Navigation Links
Investigational New Drug Application for 'Fat Melting' Injections Cleared by the FDA
Date:9/4/2007

Clinical trial on injection lipolysis treatment to begin soon

NEW YORK, Sept. 4 /PRNewswire-USNewswire/ -- The Aesthetic Surgery Education and Research Foundation (ASERF) announced today that it has received approval from the U.S. Food and Drug Administration to initiate a clinical trial investigating the safety and efficacy of one type of injection lipolysis treatment.

Treatments most properly called injection lipolysis have been commonly associated with the terms mesotherapy or fat dissolving "Lipodissolve." These types of treatments claim to reduce or eliminate unwanted local accumulations of fat, but their ingredients and injection locations and techniques may vary slightly. There is also no standardized, consistent, and accepted injection protocol or chemical formulation, with many formulas being proprietary, and without scientifically valid studies documenting their safety or effectiveness or comparing one another. Injection lipolysis involves the injection of various compounds into the subcutaneous fat, but is not currently approved by the FDA for subcutaneous injection for any purpose.

"We are pleased to finally have the approval to move forward on this important clinical trial," said V. Leroy Young, MD, chief investigator for the study. "This study is long overdue, and will go a long way toward developing more standardized protocols and ultimately improving patient safety in this area."

The study, which was designed and funded by ASERF, will be conducted under FDA supervision and will follow patients for 46 weeks to evaluate the efficacy of one form of injection lipolysis and collect data on local and systemic reactions and any long-term complications. The study will include imaging, biochemical analysis and clinical measurements for objective evaluation of the efficacy and safety of the treatment.

"Although there are clinical reports of significant and positive results, they are all anecdotal, and unfortunately there is currently insufficient scientifically valid evidence to support the long term safety and efficacy of injection lipolysis. We hope that this study will provide the data needed to clarify some of the controversy and confusion surrounding this potentially beneficial treatment. The more we know, the better we will be able to educate and inform our patients, and recommend to them, with confidence, the safest and most effective treatments to provide them with the best results," said Alan H. Gold, MD, president of ASERF.

According to the American Society for Aesthetic Plastic Surgery's 2006 Cosmetic Surgery Statistics, injection lipolysis procedures were performed last year on 28,901 Americans -- six times the number of procedures performed the previous year.

About ASERF

The Aesthetic Surgery Education and Research Foundation (ASERF) is dedicated to directed research and physician education in cosmetic plastic surgery. ASERF helps to ensure the safety and effectiveness of new aesthetic (cosmetic) plastic surgical techniques and technologies by funding scientific research and clinical studies, and helps to make new treatments with proven benefits more widely available to patients who seek to improve their quality of life through aesthetic surgery. ASERF is a charitable organization, the research arm of the Society, 100% of member donations go to clinical research. http://www.aserf.org

About ASAPS

The American Society for Aesthetic Plastic Surgery, the leading organization of board-certified plastic surgeons specializing in cosmetic plastic surgery. ASAPS active-member plastic surgeons are certified by the American Board of Plastic Surgery or the Royal College of Physicians and Surgeons of Canada. http://www.surgery.org


'/>"/>
SOURCE Aesthetic Surgery Education and Research Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Novartis files application with FDA for Zometa
6. Morepan to file new drug applications with the USFDA
7. Mini motor for micromedical applications
8. Perfusion bioreactor could enhance stem cell research and application in the future
9. Prostate Cancer Can Be Treated By Application Of LASER Technology
10. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
11. Venus Remedies Files 5th International Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: